Similarly, GPNMB inhibitors have been explored for various types of cancer, for instance the monoclonoal antibody glembatumab (CDX-011) in Phase 2 trials for melanoma and breast cancer [26,27]. The gene discussed is GPNMB; the disease is breast carcinoma.